Funding, Consortia & Accreditation

Funding

VHIO can and will only deliver on its goal of accelerating the pace in advancing personalized and targeted therapies against cancer thanks to the public funding it receives as well as the generous support from institutional supporters, private institutions, companies, associations, societies, and individual donors. As a direct reflection of VHIO's research of excellence, VHIO also continues to secure essential funding through several International and National Competitive Grants. Regarding the latter, we would like to also recognize the Asociación Española Contra el Cáncer (AECC) for its longstanding support of several VHIO groups and researchers.

Only with such continued support will the clock continue to tick in our favor - against cancer. VHIO would therefore like to express its immense gratitude to its following supporters, funding entities and agencies:


Institutional Supporters

logo
logo
logo
logo
logo

Public funding

International

logo
logo
logo
logo
logo

National

logo
logo
logo
logo
logo
logo

Private funding

logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo
logo

Consortia



Cancer Core Europe (CCE) is a unique partnership aimed at addressing the cancer care - cancer research continuum challenge. Launched in 2014, this working consortium represents a critical mass of activity for the successful integration of all cancer care information, clinical research and outcome research, led by the 6 founding partners and European comprehensive cancer centers of excellence: the Gustave Roussy Cancer Campus Grand Paris (Villejuif, France), Cambridge Cancer Centre (Cambridge, UK), Karolinska Institute (Stockholm, Sweden), Netherlands Cancer Institute – NKI (Amsterdam, The Netherlands), National Center for Tumor Diseases – DKFZ-NCT (Heidelberg, Germany), VHIO, as well as The National Cancer Institute of Milan (Italy). CEE promotes the pooling and exchange of expertise, research findings, common platforms and processes, and empowers researchers and clinicians to rapidly exploit this trove of biological insights and clinical data for the benefit of patients.

Endorsed by CCE, 2019 celebrated the official launch of the Basket of Baskets (BoB) two-stage clinical trial study, promising a more flexible and adaptive model in order to significantly accelerate patients’ access to an array of novel therapeutics.

www.cancercoreeurope.eu



COLOSSUS–Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems based patient stratification solutions, is a multi-center European Commission Horizon 2020-supported project powered by 14 leading clinical investigators and researchers spanning 8 European countries, with expertise in cancer immunology, systems biology, computational modelling, bioinformatics, omics analysis, clinical oncology/pathology, preclinical research, medical imaging, clinical trials, health economics and patient management.

This 5-year undertaking aims at better classifying and treating metastatic colorectal cancer (mCRC).

Focused on microsatellite stable RAS mutant (MSS RAS mt) disease–a genetically identified type of CRC with very few therapeutic options available once patients develop resistance to existing chemotherapies, the COLOSSUS team will strive to both expand and refine the classification of this particular subset of colorectal cancer.

www.colossusproject.eu

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 754923.



The EuroPDX Consortium–Translating Knowledge in Oncology, launched in 2013 to create a network of clinically relevant models of human cancer, and in particular patient-derived xenograft (PDX) models. Connecting 18 cancer centers across 13 countries that are developing PDX cancer models, this initiative promotes the sharing and exchange of findings on promising therapeutics as well as leads multicenter preclinical studies.

EuroPDX strives to reduce the duplication of efforts in oncology drug development and ultimately improve the quality of life and overall survival of cancer patients.

Supported by the European Union’s Horizon 2020 research and innovation programme and launched in 2018, EDIReX – EuroPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts, is led by the EuroPDX Consortium counting on the research excellence of 19 entities -including VHIO- spanning 13 European countries. The main aims of this project are to facilitate data exchange among academic and industrial preclinical and translational cancer professionals and, to spur and consolidate scientific collaborations in PDX research across Europe.

www.europdx.eu

The EDIReX project has received funding from the European Union’s Horizon 2020 research and innovation programme, grant agreement no. #731105.



Initiated in 2016, INTRACOLOR (Evolution of resistant clones to novel target-directed drugs in colorectal tumors: a genetic and epigenetic study of intratumoural heterogeneity dynamics), is supported by EU Horizon 2020 funding and led by VHIO.

Running in parallel with the Phase I/II MoTriColor trials, it incorporates 6 of MoTriColor’s members to assesses three novel targeted therapies for mCRC, each matched to distinctive gene expression signatures.

Representing a comprehensive framework for translational research, emerging molecular data is prospectively integrated in preclinical models and proof-of-concept clinical trials in mCRC. This project is carried out in collaboration with SPECTAcolor–Screening Platform for Efficient Clinical Trials Access in Colorectal Cancer, which is an initiative of the EORTC, supported by Alliance Boots.

www.motricolor.eu

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.



MESI-STRAT combines the expertise of 14 partners from 6 European countries to establish the interplay of breast cancer metabolism and oncogenic signaling (Metabolic Signaling) by systems medicine approaches. Aimed at developing new models for knowledge-based STRATification of patients into subgroups with different endocrine therapy resistance mechanisms, this pan-European 57-month project, supported by the European Union’s Horizon 2020 research and innovation programme, represents an important forward step towards improving outcomes for these patients.

The team pioneers breast cancer metabolism as a novel approach for the stratification of patients, tracking of resistance and better guiding clinical decision-making throughout the course of endocrine therapy. Through the development of new computational models in combination with network analyses, pharmacogenomics and integrated multi-omics data, MESI-STRAT will play a decisive role in better deciphering the metabolic and signaling networks that drive resistance to endocrine-based therapies.

www.mesi-strat.eu

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 754688.



Spurred by Horizon 2020’s European Union funding for Research and Innovation funding, MoTriColor (Molecularly guided Trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of Colorectal cancer), led by VHIO, is powered by 8 clinical research centers of excellence, spanning Spain, Italy, The Netherlands and Belgium, as well as a European organization in cancer research and a diagnostic/prognostic SME.

Dedicated to conducting multi-center early phase clinical trials to establish the anti-tumor activity of novel experimental therapies for patients with metastatic or advanced colorectal cancer, patients are stratified based on their gene expression profiles according to recently established predictive signatures.

This pioneering approach aims at identifying sensitivity of individual patients to the proposed experimental therapies towards ultimately developing more precise anti-cancer therapies for these patients.

www.motricolor.eu

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 635342.



Funded through a grant received from the European Union’s Horizon 2020 research and innovation programme, the NoCanTher–Nanomedicine upscaling for early clinical phases of multimodal cancer therapy is a multi-center–Consortium is led by IMDEA Nanoscience and represents an important forward step in utilizing nanoparticles than can better target and more precisely combat cancer cells.

It builds on the preclinical successes reported by the former FP7-funded MultiFun Consortium that evidenced the efficacy of a multi-modal therapeutic approach based on functionalized magnetic nanoparticles and magnetic hyperthermia for the intra-tumoral treatment of breast and pancreatic tumors.

Connecting 11 leading European research centers, including industry partners, NoCanTher assesses this nano-based approach and provide preliminary data on its efficacy in humans and aim to translate these preclinical findings into early clinical development for the treatment of pancreatic cancer.

www.nocanther-project.eu

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 685795.



The PhD PI3K biology in health & disease Network incorporates 10 academic, clinical and industrial partners with renowned expertise in research focused on PI3K signaling. Leading a unique training network, this collaboration connects complementary expertise and brings additional value, novel tools and leadership of excellence in order to train talented early stage researchers and suitably equip them for leading roles in cancer science and drug discovery in European industry and academia.

This research training programe not only represents unparalleled educational opportunity for these young scientists, but also aims to increase the international competitiveness of European research in PI3K discovery and drug development.

www.pi3k-phdproject.eu



Incorporating a network of 27 research entities spanning 10 countries, SPECTAcolor - Screening Platform for Efficient Clinical Trials Access in Colorectal cancer, is an initiative within the framework of the research program of the EORTC, supported by Alliance Boots.

Launched in 2013, this is the first prospective fully annotated tumor samples Biobank and Biomarker analysis platform for genetic profiling of patients suffering from advanced colorectal cancer.

https://www.eortc.org/blog/category/spectacolor



The Spanish Association against Cancer (AECC), and the Institute of Health Carlos III (ISCIII) through the ERA-NET: Aligning national/regional translational cancer research activities awarded VHIO with two TRANSCAN-2 projects funded by the EU's Horizon 2020 framework program in 2017.

Supported through the TRANSCAN Joint Translational Call on Minimally and non-invasive methods for early detection and/or progression of cancer, the first will establish non-invasive prognostic markers for resected early-stage non-small cell lung cancer (NSCLC) by assessing the role of circulating and exosomal miRNAs and free circulating DNA (fcDNA); as well as characterize blood-based tumor-educate platelets (TEPs) for the evaluation of patients treated with immune checkpoint inhibitors using novel sequencing technologies.

The second project will focus on the early detection of relapse in advanced colon cancer patients by longitudinally following a personalized molecular signature by liquid biopsy. This proof-of-concept, prospective, multi-center study will primarily seek to evaluate the clinical feasibility of tracking tumor progression by dynamically detecting a molecular and personalized signature from a blood test.

www.transcanfp7.eu

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.



Announced in 2018, one of the U.S. Department of Defense’s (DoD) Innovative Minds in Prostate Cancer (IMPaCT) Awards funds a three- year collaborative partnership to advance precision medicine against metastatic prostate cancer (mPC). This coalition will count on the multidisciplinary expertise of investigators at VHIO, the Spanish National Cancer Research Centre–CNIO (Madrid, Spain), and the University of Washington (USA).

Aimed at more precisely gauging response in patients to standard therapies, the team seeks to develop new, more effective and tailored treatment strategies, as well as design a clinical trial to assess the performance of a DNA damaging platinum chemotherapy, carboplatin, that is already used to treat other tumor types including ovarian and breast cancer.

https://cdmrp.army.mil/pcrp



WIN - Worldwide Innovative Networking in personalized cancer medicine, initiated by the Institut Gustave Roussy (France) and The University of Texas, MD Anderson Cancer Center (USA) is a non-profit, non-governmental organization incorporating 39 leading organizations representing all stakeholders in personalized cancer medicine covering 21 countries and 4 continents, united by their vision to deliver on the promise of effective, personalized cancer medicine to patients worldwide.

Under the tagline WINning together, WIN was formed on the premise that members can accomplish more together than each organization can achieve working alone. Aimed at improving cancer patients’ survival and quality of life, WIN members also collaboratively design and carry out global studies designed to achieve breakthroughs for cancer patients across the globe.

www.winconsortium.org



New Consortia – officially launched in 2019


Announced at the beginning of 2019, the OPTIMISTICC Grand Challenge – Opportunity To Investigate the Microbiome’s Impact on Science and Treatment In Colorectal Cancer- is a 5-year consortium funded by Cancer Research UK’s Grand Challenge, led by researchers at the Dana-Farber Cancer Institute-Harvard Medical School, and Harvard T.H. Chan School of Public Health (USA). Aimed at better understanding the difference between a healthy microbiome and a microbiome associated with the development of colorectal cancer, the co-investigators from the US, Canada, the UK, Netherlands, and Spain, are seeking to identify ways to manipulate this collection of microorganisms to better prevent and treat cancer.

It is thanks to the Grand Challenge Funding that the project partners, including VHIO, are able to pool the necessary expertise in order to establish how the microbiome influences a cancer’s response to treatment, develop new treatments that alter the microbiome, and decipher how an individual’s external environment may affect their microbiome.

www.optimisticc.org



EUCanCAN – the European-Canadian Cancer Network, led by the Barcelona Supercomputing Center (Spain), comprises a total of 18 partners from 5 different countries to pursue the homogeneous analysis, management and exchange of genomic-driven oncology data to advance precision medicine in cancer.

Jointly funded by the European Union’s Horizon 2020 research and innovation programme and the Canadian Institutes of Health, this project strives to provide a functional platform for federated genome analysis systems towards efficiently analyzing, managing, sharing and reusing mass genomic data at the global level. The participating reference nodes seek to process, store and share between 30-35 thousand patient samples across various tumor types.

This consortium also promises to drive discovery into robust and clinically-relevant patterns of genomic variation in cancer, including predictive biomarkers.

www.eucancan.com

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825835.



Immune-Image is a 22 stakeholder-strong consortium incorporating public and private partners across 9 countries, including VHIO and the Vall d’Hebron Institute of Research (VHIR) from Spain. Powered by the Innovative Medicines Initiative Joint Undertaking (IMI 2 JU), this initiative is led by Roche and coordinated by the Amsterdam University Medical Center (VUmC), The Netherlands. Set to run for an initial duration of five years, this project is entitled Specific imaging of immune cell dynamics using novel tracer strategies, and seeks to develop a novel non-invasive imaging strategy for assessing immune cell activation and dynamics in oncology and inflammatory disease.

Main deliverables include developing clinically validated radio-and optical immunotracers for the monitoring and measurement of immune cell presence, activation status and trafficking, and designing and implementing a ready-to-use sustainable molecular imaging platform, incorporating standardized protocols, best practices, quantitative image analyses, immune-based tracking design and development.

www.immune-image.eu



Funded by the European Union’s Horizon 2020 research and innovation programme, the CELAC and European Consortium for a Personalized Medicine Approach to Gastric Cancer (LEGACy) is a 4-year project spearhead by INCLIVA Health Research Institute (Spain), in partnership with 10 other members across 9 different countries including VHIO.

Focused on advancing personalized medicine against gastric cancer, this project aims to improve diagnosis and treatment by using data obtained through extensive research in four EU countries and four countries within the Community of Latin American and Caribbean (CELAC). States outcomes by applying personalized medicine at the three levels of prevention. This consortium will seek to implement a personalized medicine strategy at the first level of prevention, improve early gastric cancer detection at the second level of prevention, and improve treatment through the identification of high-risk populations.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 825832.



RADprecise - Personalized radiotherapy: Incorporating cellular response to irradiation in personalized treatment planning to minimise radiation toxicity, is supported by funding received through ERAPerMed’s co-funded Joint Translational Call 2018* and was founded in 2019 by 7 leading organisations from Spain, Italy, Germany and France. This 3-year project will render radiotherapy more precise by incorporating data from finely tuned predictive models to pre-identify toxicity based on insights from multiple biomarkers of radiosensitivity in individual patients.

Led by colleagues at the German Cancer Research Center (DKFZ), Germany, project partners will apply findings at the clinical level by integrating a treatment planning system. Using parametric models and machine learning, clinical investigators from academia and health research, in collaboration with small and medium enterprises as well as patient advocates, will apply new biological data as well as readily available genomic information to develop models that can more precisely envisage adverse effects from radiotherapy to be validated in independent samples.

www.erapermed.eu

*This project has received funding from the European Union's Horizon 2020 Research and Innovation Programme under Grant Agreement No. 779282



Other collaborations:


The AstraZeneca VHIO Alliance announced in 2015, and the MedImmune VHIO Alliance launched in 2018, drive advancements at preclinical, clinical and translational research levels across the AstraZeneca's oncology portfolio. Combining VHIO's strengths in promoting cancer discovery through the integration of translational science and clinical research with AstraZeneca's promising early stage oncology pipeline, the alliance focuses on areas including DNA damage repair, drug resistance, new drug combinations and molecular profiles for patient selection.

Bookmark and visit VHIO's website for forthcoming updates:
www.vhio.net



The SCITRON Consorcio público-privado de Investigación Científica y Translacional en Oncología (Consortium for Scientific Translational Research in Oncology) is a scientific program established in collaboration with Novartis in 2017 as a new model of R&D collaboration. This initiative connects expertise from Novartis and VHIO in applied and translational research to increase the impact of basic research in clinical practice.

The specific areas of interest include the development of a technology platform that analyses tumor clonal evolution and resistance mechanisms to targeted immunotherapy.

www.novartis.com



Launched by Roche in 2016, the imCORE - immunotherapy Centres of Research Excellence Network - a 21-strong academic powerhouse set to progress discovery in cancer immunotherapy, brings together internationally renowned scientific and clinical experts in cancer immunotherapy to collaborate in investigating the most promising novel treatment approaches.

Working in collaboration with scientists from Roche and Genentech, researchers and physician-scientists in cancer immunotherapy from across the globe aim to drive the application and extension of immune-based strategies to more tumor types, as well as advance research into the cellular and molecular mechanisms modulating immune response to cancer.

This Network was designed to significantly advance anti-cancer immunotherapeutics and accelerate discovery towards benefiting patients who may stand to gain from novel immune agents as mono therapy or in combination.

www.roche.com



The OCTC - Oncology Clinical and Translational Consortium, a collaborative scientific research network comprised of 6 renowned comprehensive cancer centers, was launched by GSK in 2013. While GSK gains OCTC's expertise in preclinical, translational and clinical development of novel anticancer therapeutics, the participating centers have access to studies with GSK's early stage oncology pipeline and opportunities to accelerate and advance the next generation of novel oncology therapeutics.

www.gsk.com

Accreditation



In 2017 VHIO underwent evaluation for accreditation of the CERCA Institute of Research Centres of Catalunya (Institució CERCA–Centres de Recerca de Catalunya) for the period 2013–2016.

In recognition of VHIO's progress, performance in knowledge transfer activities and management of excellence, VHIO was awarded the maximum qualification of an A grading.



The European Commission’s Human Resources for Research (HRS4R) strategy enables research institutions of excellence to actively implement and uphold the requisites of The European Charter for Researchers and Code of Conduct for the Recruitment of Researchers for their HR policies and practices.

VHIO’s comprehensive analysis and action plan was officially approved by HRS4R assessors in 2018 and our Institute was consequently granted permission to use the HR Excellence in Research Award logo as demonstration of its stimulating and favorable work environment.

www.vhio.net/en/hr-excellence-research



Also reflecting our dedication to excellence and the quality of our services and procedures, our Cancer Genomics and Molecular Groups are both ISO 15189 accredited for their testing methods and technologies. Similarly, we continue to meet the high standards in quality and procedures in the audit of our clinical trials Units, carried out by the Generalitat de Catalunya. Our Research Management is also endorsed by ISO 9001 Certification.

New funding and projects in 2019


Departament de Salut: Budgetary support
Departament d’Empresa i Coneixement: Budgetary support


VHIO’s CELLEX Building & Infrastructure


Advanced Molecular Diagnostics Program (DIAMAV), and other VHIO investigators, groups and projects


Research Unit for Molecular Therapy of Cancer (UITM) - "la Caixa", and "la Caixa" International Program for Cancer Research and Education


Comprehensive Program of Cancer Immunotherapy & Immunology (CAIMI)


International Support


Innovative Medicine Initiative (IMI) – International Consortium
Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies
PI VHIO: Josep Tabernero
Gastrointestinal and Endocrine Tumors Group
SC1-BHC-10-2019 Pre-Commmercial Procurement (PCP)– INTERNATIONAL CONSORTIUM
oncNGS: NGS diagnostics in 21st century oncology: the best, for all, at all times
PI VHIO: Josep Tabernero
Gastrointestinal and Endocrine Tumors Group
Marie Skiodowska-Curie Individual Fellowships
AR-DDR: Co-targeting androgen receptor signalling and DNA damage repair for precision therapy
Granted to Joaquín Mateo
Prostate Cancer Translational Research Group


Grand Challenge International Consortium
OPTIMISTICC: OPportunity To Investigate the Microbiome’s Impact on Science and Treatment In Colorectal Cancer
PI VHIO: Josep Tabernero
Gastrointestinal and Endocrine Tumors Group


Breast Cancer Now Catalyst Programme Modulation of androgen receptor signaling as a therapeutic strategy for oestrogen receptor-positive metastatic breast cancer PI: Violeta Serra Experimental Therapeutics Group


Clinical Unit Visit
Granted to Joao Pedro de Almeida Moreira Pinto
Mentor: Teresa Macarulla
Gastrointestinal and Endocrine Tumors Group
Clinical/ Research Fellowship
Evaluation of Immunological Activity Markers in Patients with Metastatic Cancer receiving checkpoint inhibitors
Granted to Vladimir Galvao
Mentor: Elena Garralda
Early Clinical Drug Development Group


Breast Cancer Research Foundation Grant
Novel therapies against HER2-positive breast tumors: targeting oncogene-induced senescence and the immune system
PI: Joaquín Arribas
Growth Factors Group


Breast Cancer Research Foundation Grant
Novel therapies against HER2-positive breast tumors: targeting oncogene-induced senescence and the immune system
PI: Joaquín Arribas
Growth Factors Group


Beca Internacional de Posgrado
Granted to Daniel Pilco
Mentor: César Serrano
Sarcoma Translational Research Group


National Funding


Ajuts per a xarxes d’R+D+I per a dur a terme programes de valortizació i transferencia dels resultats de recerca Catalan Consortium
Valorització de l’Arxiu Europeu de Genoma-Fenoma (EGA) per la Indústria i la Societat (VEIS)
PI VHIO: Rodrigo Dienstmann
Oncology Data Science Group (ODysSey)
Beatriu de Pinos:
In-depth profiling of neoantigen specific-lymphocyte subsets with superior traits for personalized T cell therapies
Granted to Jara Palomero
Tumor Immunology & Immunotherapy Group
FI-Predoctoral DGR:
Modulació de la senyalització del receptor d'androgen com a estratègia terapèutica pel càncer de mama metastàsic estrogen-positiu resistent a inhibidors de CDK4/6 i PI3K
Granted to Laia Monserrat
Experimental Therapeutics Group
FI-Predoctoral DGR:
Identification of Novel Micropeptides Involved in Lung Cancer Stemness: New Cancer Players for New Therapies Granted to Olga Boix
Cellular Plasticity and Cancer Group


CERCA Accreditation’s associated program incentives


DEPARTAMENT DE SALUT
Intesificació de Professionals amb formació Sanitaria Especialitzada
Impacte del seguiment longitudinal en càncer colorrectal estadi III i avançat mitjançant una signatura molecular personalitzada en biòpsia líquida
PI: Elena Élez
Gastrointestinal and Endocrine Tumors Group
Joves Investigadors Doctors
Nou anàlisi combinat de biopsia liquida per a monitoritzar l’evolució genómica tumoral i la resposta a tractaments dirigits en cáncer de prostata
Granted to Irene Casanova
Prostate Cancer Translational Research Group
Projectes de Recerca en Medicina Personalitzada (ERA PerMed) INTERNATIONAL CONSORTIUM
Personalized radiotherapy: incorporating cellular response to irradiation in personalized treatment planning to minimize radiation toxicity (RADprecise)
PI VHIO: Sara Gutiérrez Enríquez
Hereditary Cancer Genetics Group
Consolidació de les unitats de promoció de projectes de R+D+I Internacionals (Go Europe)
Implementación de mejoras en la solicitud de ayudas internacionales. Consolidación de la Oficina de Proyectos UE de VHIO. MATCH Program: Ideas - Oportunidades
PI: Alejandro Piris


Proyectos I+D Retos
Explotando el Microproteoma para Encontrar Nuevas Dianas Moleculares contra el Cáncer
PI: Maria Abad
Cellular Plasticity and Cancer Group
Ayudas para la Contratos Juan de la Cierva Formación
Granted to Laura Escudero
Gene Expression and Cancer Group
Ayudas para la Contratación de Personal Técnico de Apoyo (PTA)
Granted to Agatha Martín
Cancer Genomics Group


VHIO projects managed through the Instituto de Investigación Sanitaria Acreditdo Institut de Recerca (Accredited Research Institute - Vall d'Hebron


Proyectos de Investigación en Salud
Immunotherapy against HER2 positive tumors / Inmunoterapia contra tumores HER2 positivos
PI: Joaquín Arribas
Growth Factors Group
Proyectos de Investigación en Salud
Understanding the Immunosuppressive Tumor Microenvironment in Brain Cancer
PI: Joan Seoane
Gene Expression and Cancer Group
Proyectos de Investigación en Salud
Validación de una nueva terapia anti-Myc en melanoma
PI: Laura Soucek
Mouse Models of Cancer Therapies Group
Proyectos de Investigación en Salud
Diagnostic and Therapeutic implications of the HMGA1-RAGE signaling pathway in Triple Negative Breast Cancer
PI: Josep Villanueva
Tumor Biomarkers Group
Proyectos de Investigación en Salud
Towards an accurate estimation of cancer risk and individualization of medical management by applying the Polygenic Risk Score (PRS) in hereditary breast and ovarian cancer
PI: Judith Balmaña
Hereditary Cancer Genetics Group
Proyectos de Investigación en Salud
Comprehensive RNA expression and DNA repair functional analysis of clinically actionable hereditary breast/ovarian cancer genes in patients with uninformative multi-gene panel result
PI: Sara Gutiérrez-Enríquez
Hereditary Cancer Genetics Group
Proyectos de Investigación en Salud
Comprehensive RNA expression and DNA repair functional analysis of clinically actionable hereditary breast/ovarian cancer genes in patients with uninformative multi-gene panel result
PI: César Serrano
Sarcoma Translational Research Group
Proyectos de Programación Conjunta Internacional INTERNATIONAL CONSORTIUM ERAPERMED
Patient stratification based on DNA repair functionality for cancer precision medicine (RAD51predict)
COORDINATOR VHIO: Violeta Serra
Experimental Therapeutics Group
Miguel SERVET
Exploiting senescence in a two-step approach to treat metastatic Prostate Cancer
Granted to Nicolás Herranz
Prostate Cancer Translational Research Group
Miguel SERVET Tipo II
Granted to Violeta Serra
Experimental Therapeutics Group
Ayudas para la Intensificación de la Actividad Investigadora
Granted to Pau Abrisqueta
Experimental Hematology Group
Ayudas para Contratos Predoctorales de Formación en Investigación en Salud
Granted to Sara Arce
Prostate Cancer Translational Research Group
Ayudas para Contratos Predoctorales de Formación en Investigación en Salud
Granted to Miranda Fernandez
Experimental Hematology Group


Convocatoria para Adjudicación de Ayuda para Proyectos de Investigación en Salud
Identificación y Análisis del Microproteoma del Cáncer de Páncreas: Los Micropéptidos como Nuevas Dianas Terapéuticas y Biomarcadores Tumorales
PI: Maria Abad
Cellular Plasticity and Cancer Group


Ayudas Predoctorales InPhinit Incoming
Granted to Flaminia Pedretti
Mentor: Violeta Serra
Experimental Therapeutics Group
Ayudas Predoctorales InPhinit Incoming
Granted to Queralt Serra
Mentor: Sandra Peiró
Chromatin Dynamics in Cancer Group


Private Funding


Health Research_NATIONAL CONSORTIUM:
Defining The Role of Exosome-Secreted Micropeptides in Pancreatic Cancer
Coordinator VHIO: Maria Abad
Cellular Plasticity and Cancer Group


Beca FERO en Investigación Oncológica Traslacional
Novel approaches to liquid biopsy in prostate cancer to inform precision medicine
PI: Joaquin Mateo
Prostate Cancer Translational Research Group
Proyectos FERO-GHD en Cáncer de Mama
Development of a liquid biopsy test to assess the homologous recombination function status in BRCA1/2 mutation carriers with breast cancer to inform therapy selection
PI: Violeta Serra
Experimental Therapeutics Group
Pronóstico precoz de la recaída tumoral en una gota de sangre – Marnaton
PI: Héctor G. Palmer
Stem Cells and Cancer Group


ERAPERMED - INTERNATIONAL CONSORTIUM
Patient stratification based on DNA repair functionality for cancer precision medicine
Coordinator VHIO: Violeta Serra
Experimental Therapeutics Group
ACCELERATOR - INTERNATIONAL CONSORTIUM
PREDICT-Meso: PRE-malignant Drivers Combined with Target-Drug validation in Mesothelioma
PI VHIO: Susana Cedrés
Thoracic Tumors & Head and Neck Group
ACCELERATOR - INTERNATIONAL CONSORTIUM
SMART Experimental Cancer Medicine Trials eNABLED
PI VHIO: Elena Garralda
Early Clinical Drug Development Group
ACCELERATOR - INTERNATIONAL CONSORTIUM
Pseudomyxoma peritonei: building a European multicentric cohort to accelerate new therapeutic perspectives
PI VHIO: Héctor G. Palmer
Stem Cells and Cancer Group
Grupos Coordinados AECC – NATIONAL CONSORTIUM
Redirección de células T contra tumores dirigidos por HER2
Coordinator VHIO: Joaquín Arribas
Co-PI VHIO: Elena Garralda
Co-PI VHIO: Francesc Bosch
Growth Factors Group
Early Clinical Drug Development Group
Experimental Hematology Group
Ideas Semilla
Optimización del uso de inhibidores de checkpoint en pacientes con neoplasias linfoides que reciben un trasplante alogénico de progenitores hematopoyético
PI: Pere Barba
Experimental Hematology Group
Clínico Senior AECC
Métodos mínimamente invasivos y no invasivos para la detección precoz y / o progresión del cáncer colorrectal incluyendo el estudio del pronóstico y predictivo del ADN tumoral circulante en la enfermedad avanzada.
Granted to Elena Élez
Mentor Josep Tabernero
Gastrointestinal and Endocrine Tumors Group
Investigador AECC
Tumores primarios múltiples en pacientes con cáncer de pulmón: elaboración de un perfil molecular integral para elucidar orígenes genéticos comunes
Granted to Miriam Sansó
Mentor Ana Vivancos
Cancer Genomics Group


Concurso Nacional para la adjudicación de Ayudas a la Investigación en Ciencias de la Vida y de la Materia
Identification of novel immunotherapeutic targets in lung and melanoma brain metastases
PI: Joan Seoane
Gene Expression and Cancer Group


Becas Gilead a la Investigación Biomédica
Understanding the tumor immune microenvironment in diffuse large B-cell lymphoma for the development of immunotherapeutic strategies that target each individual's immune biology
PI: Francesc Bosch
Experimental Hematology Group


Programa Joves i Ciència
PI: Violeta Serra
Experimental Therapeutics Group
Programa Joves i Ciència
Mentor: Joan Seoane
Gene Expression and Cancer Group


Ayuda para proyectos de Investigación de Secciones y Grupos de Trabajo Registro prospectivo Sección de Cáncer Hereditario SEOM de personas portadoras de variantes en nuevos genes de susceptibilidad al cáncer PI: Judith Balmaña Hereditary Cancer Genetics Group


Convocatoria d’Ajuts a la Investigació Oncològica
Caracterització epigenètica dels colangiocarcinomes
PI: Sandra Peiró
Chromatin Dynamics in Cancer Group
Convocatoria d’Ajuts a la Investigació Oncològica
Immunoteràpia personalitzada per a càncer d'endometri
PI: Alena Gros
Tumor Immunology & Immunotherapy Group
Convocatoria d’Ajuts a la Investigació Oncològica
Estudi i implicacions translacionals de l'evasió del sistema immunitari en la leucèmia limfàtica crónica
PI: Francesc Bosch
Experimental Hematology Group
Convocatoria d’Ajuts a la Investigació Oncològica
El microambient immune tumoral en la patogènesi i control del limfoma de cèl·lules del mantell
PI: Josep Villanueva
Tumor Biomarkers Group
Convocatoria d’Ajuts a la Investigació Oncològica
Superant la resistència a les immunoteràpues a través de la inhibició de Myc en càncer de pulmó mutat en KRAS amb perfils mutacionals diversos
PI: Laura Soucek
Mouse Models of Cancer Therapies Group
Convocatoria d’Ajuts a la Investigació Oncològica
Implementació de la biòpsia líquida més enllà de les aplicacions actuals: estudi prospectiu del valor pronòstic i predictiu de l'ADN tumoral circulant en càncer colorectal metastàtic
PI: Elena Élez
Gastrointestinal and Endocrine Tumors Group
Convocatoria d’Ajuts a la Investigació Oncològica
PrecIMet: imatge de precisió per a l'avaluació de metàstasis òssies
PI: Raquel Pérez-López
Radiomics Group
Convocatoria d’Ajuts a la Investigació Oncològica
Biòpsies líquides per a la identificació de mecanismes de resistència als inhibidors de PARP en càncers associats a BRCA1/2
PI: Violeta Serra
Experimental Therapeutics Group


STOP FUGA DE CEREBROS
Senescent cells as a therapeutic target against breast cancer
Granted to Verónica Rodilla
Mentor Joaquín Arribas
Growth Factors Group


Beca Junior Getne Proyecto de Investigación 2018
Análisis de marcadores pronósticos y predictivos de respuesta a inhibidores de tirosina quinasa en cáncer diferenciado de tiroides a partir de patrones de metilación del ADN
PI: Jorge Hernando
Gastrointestinal and Endocrine Tumors Group


IRONMAN-ES: Estudio prospectivo observacional de parámetros clinicos y biomarcadores en cáncer de próstata avanzado en hospitales de España
PI: Joaquín Mateo
Prostate Cancer Translational Research Group


Pronóstico y control de peso en pacientes con cáncer de mama mediante una intervención de dieta y ejercicio (PREDICOP)
PI: Cristina Saura
Breast Cancer and Melanoma Group


BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation
PI: Susana Muñoz


Donacions Campanya Mocador Solidari
PI: Cristina Saura
Breast Cancer and Melanoma Group